Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "PhRMA" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about PhRMA for you to read. Along with our medical data and news we also list PhRMA Clinical Trials, which are updated daily. BioPortfolio also has a large database of PhRMA Companies for you to search.
Spending on medicines is growing at the slowest rate in years, but according to a new IQVIA Institute for Human Data Science article, at the pharmacy, commercially insured patients with a deductible have their seen out-of-pocket costs for brand medicines increase 50 percent since 2014. The data also show 55 percent of patien
The U.S. patent system has supported innovation and discovery dating back to the founding of our nation and the signing of the U.S. Constitution, encouraging Americans to continue to search for the next great idea or product. Today marks a major milestone in the history of American innovation as the United States Patent and Trademark Office (USPTO) issued its 10 millionth
As part of the broader shift away from paying for volume to paying for value in health care, payors are increasingly pursuing value-based or results-based contracts with biopharmaceutical companies. These innovative payment arrangements can help deliver savings for patients, private payors and the government in addition to the potential for better clinical outcomes. Recent, long-awaited final guid...
Did you know 340B hospitals prescribe more medicines or more expensive medicines? A recent analysis by Milliman, commissioned by PhRMA, found hospitals participating in the 340B drug pricing program have higher per
For more than a decade, Medicare Part D has successfully provided seniors comprehensive prescription drug coverage that meets their needs, while its market-based structure has kept overall program costs far below initial projections. But the program could work even better by improving affordability and predictability for seniors who are facing high out-of-pocket costs.
This week, the new era of medicine was brought to Capitol Hill in Washington, DC when 55 biopharmaceutical researchers from 20 PhRMA member companies held 79 meetings with members of Congress and their staff. Conversations focused on the life-saving work researchers do each and every day to bring new treatments and cures to patients. During their meetings, researchers shared their own ...
This month, PhRMA is proud to join with our member companies to celebrate Lesbian, Gay, Bisexual and Transgender (LGBT) PRIDE Month.
In the past year, we have seen revolutionary new treatments become available to patients in the United States for cancer and other debilitating diseases. A new analysis puts in perspective the greater availability of new therapies for American patients compared to those living in other countries.
In health care, who should decide value? In many industrialized countries with single-payer health systems, the answer is “the government.” A new analysis by Avalere illustrates the negative impact this answer has on patient access to care.
At the end of April, the Supreme Court decided two cases concerning the inter partes review (IPR) proceedings enacted as part of the 2011 America Invents Act (AIA). While distinct cases, together they have implications for the future of the IPR process.
Amidst debate about rising health care costs, some policy-makers have expressed renewed interest in using cost-effectiveness thresholds as the basis for setting coverage and payment policy. But a new analysis
In the not too distant past, chemotherapy and radiation were once the only treatments for what remains the second leading cause of death in the United States – cancer. Although the death rates of cancer have declined in the past 20 years and survival rates have increased by five times since the 1970s, there is still more work to be done. The
Health care issues are often so highly politicized that it’s easy to lose sight of the people behind the scenes, especially the millions of medical professionals that wake up each morning with a drive to help people. While news headlines focus on controversy, these people focus on finding answers for patients and preventing and curing disease.
A recent study conducted by the Academy of Managed Care Pharmacy (AMCP) and Xcenda found that 71 percent of insurers and 63 percent of biopharmaceutical companies surveyed were interested in pursuing outcomes-based contracts, one type of value-based contract (also known as
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.
A new study found that if all migraine sufferers used an emerging class of preventative migraine treatments, the United States could save $396 billion in indirect costs over ten years and avoid 374 mill
A new study found that if all migraine sufferers used an emerging class of preventative migraine treatments, the United States could save $396 billion in indirect costs and avoid 374 million migraine da
Despite the current unprecedented pace of biopharmaceutical innovation, patients continue to face rising out-of-pocket costs and other barriers to care. Tomorrow, in partnership with The Atlantic, PhRMA will bring together industry experts, thought-leaders and other stakeholders to examine these challenges and to explore ways we can move towards a value-d
A new report from the Tufts Center for the Study of Drug Development finds that it takes 2.3 years, or 18 percent, longer to develop an orphan drug compared with medicines to treat more common conditions. Although clinical trials for orphan diseases – defined as aff
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less ...
Sharing a portion of negotiated rebates at the pharmacy counter could save seniors in Medicare with diabetes more than $350 annually, according to a new analysis from IHS Markit. The data also show sharing negotiated rebates could save Medicare nearly $1000 annually for every senior taking
May is World Trade Month, when we celebrate the many American companies exporting products around the world, and growing opportunities here in the U.S.
Today, we are launching the “Let’s Talk About Medicare” advertising campaign focused on solutions to improve affordability and predictability for seniors in Medicare Part D. Similar to how the “Let’s Talk About Cost” campaign opened up a conversation about costs and prescription drug coverage, this c
Yesterday, PhRMA president and CEO Stephen J. Ubl spoke at POLITICO’s “Deconstructing the Prescription Drug Supply Chain” event, discussing the incredible new era of medicine, medicine spending trends, biopharmaceutical supply chain dynamics and market-based solutions to improve patient